The association of germline CDH1 mutations and HDGC predisposition was a breakthrough that sparked the establishment of specific guidelines for genetic screening and surveillance of patients who are at high risk of developing GC [27] However, current CDH1 genetic testing guidelines neglect worldwide distribution of variants, in part because such information has not been carefully curated. The gene discussed is CDH1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.